Pharma BD Deal Intelligence

Hanmi Pharmaceutical Co. Ltd. / Boehringer Ingelheim GmbH

2016 · Licensing/Option · $730M · Terminated

Boehringer Ingelheim terminated its July 2015 license/collaboration with Hanmi Pharmaceutical for olmutinib (HM61713), a 3rd-generation EGFR inhibitor for T790M-mutant NSCLC. Original deal: $50M upfront plus up to $680M in milestones plus tiered double-digit royalties (~$730M total). Termination triggered by Korean safety alerts (toxic epidermal necrolysis cases including one fatal SJS) and competitive pressure from AstraZeneca's Tagrisso. Hanmi retained $65M already received.

Key facts

• Announced Sep 30, 2016
• Deal value $730M
• Deal type Licensing/Option
• Therapeutic area EGFR T790M-mutant non-small cell lung cancer
• Indications EGFR T790M-mutant non-small cell lung cancer
• Key assets Olmutinib (HM61713)
• Mechanism 3rd-generation irreversible EGFR mutation-selective tyrosine kinase inhibitor

← Browse all deals  ·  How we score deals